5-(chloromethyl)-2-methyl-2H-indazole | 1824466-73-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 5-(chloromethyl)-2-methyl-2H-indazole
• 英文别名: 5-(chloromethyl)-2-methylindazole
• CAS: 1824466-73-0
• 化学式: C₉H₉ClN₂
• 分子量: 180.637
• InChiKey: DEIHYPIXKGWCPR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-((3S,4S)-4-hydroxytetrahydro-2H-pyran-3-yl)-7,8-dimethyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[e][1,3]oxazin-4(3H)-one 、 5-(chloromethyl)-2-methyl-2H-indazole 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 乙二醇二甲醚 、 水 为溶剂， 以0.03 g的产率得到1,5-anhydro-2,4-dideoxy-2-(7,8-dimethyl-6-((2-methyl-2H-indazol-5-yl)methyl)-4-oxo-2H-1,3-benzoxazin-3(4H)-yl)-L-threo-pentitol
  参考文献：
  名称：

  [EN] 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR
  [FR] DÉRIVÉS DE 2,3-DIHYDRO-4 H-1,3-BENZOXAZIN-4-ONE COMME MODULATEURS DU RÉCEPTEUR M1 MUSCARINIQUE CHOLINERGIQUE

  摘要：

  本发明提供一种具有胆碱能乙酰胆碱受体M1阳性变构调节剂活性的化合物，该化合物可能用作治疗或预防阿尔茨海默病、精神分裂症、疼痛、睡眠障碍、帕金森病痴呆、李威氏体痴呆等疾病的药物。本发明涉及一种由式(I)或其盐表示的化合物：其中每个符号如附图中所定义。

  公开号：

  WO2016208775A1

文献信息

• Heterocyclic compound
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US10087150B2

  公开（公告）日：2018-10-02

  The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

  本发明提供了一种具有胆碱能毒蕈碱 M1 受体正异位调节剂活性的化合物，该化合物可用作阿尔茨海默病、精神分裂症、疼痛、睡眠障碍、帕金森病痴呆、路易体痴呆等的预防或治疗药物。本发明涉及一种由式（I）代表的化合物或其盐： 其中各符号如所附说明书中定义。
• 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US10323027B2

  公开（公告）日：2019-06-18

  The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.

  本发明提供了一种具有胆碱能毒蕈碱M1受体正异位调节剂活性的化合物，它可作为阿尔茨海默病、精神分裂症、疼痛、睡眠障碍、帕金森病痴呆、路易体痴呆等的预防或治疗药物。本发明涉及一种由式（I）代表的化合物或其盐：其中各符号如所附说明书中定义。
• 2,3-DIHYDRO-4H-1,3-BENZOXAZIN-4-ONE DERIVATIVES AS MODULATORS OF CHOLINERGIC MUSCARINIC M1 RECEPTOR
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP3313836A1

  公开（公告）日：2018-05-02
• HETEROCYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：US20160376244A1

  公开（公告）日：2016-12-29

  The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.
• US9878989B2
  申请人：——

  公开号：US9878989B2

  公开（公告）日：2018-01-30